Targeting ribosylation by inhibiting AGE formation may be a promising therapeutic strategy to prevent Alzheimer’s disease-like Tau hyperphosphorylation and diabetic encephalopathies. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.